Saint-Cloud, France

Jean-Christophe Gueguen


Average Co-Inventor Count = 8.5

ph-index = 2

Forward Citations = 48(Granted Patents)


Location History:

  • Saint-Cloud, FR (1995)
  • Chatenay-Malabry, FR (1999)

Company Filing History:


Years Active: 1995-1999

Loading Chart...
2 patents (USPTO):Explore Patents

Title: The Innovations of Jean-Christophe Gueguen

Introduction

Jean-Christophe Gueguen is a notable inventor based in Saint-Cloud, France. He has made significant contributions to the field of pharmaceuticals, particularly in the development of innovative compounds. With a total of 2 patents to his name, Gueguen's work has had a meaningful impact on medical treatments.

Latest Patents

Gueguen's latest patents include groundbreaking research on Cyclosporin derivatives. These derivatives are described as useful for the treatment and/or prophylaxis of retrovirus infections. The specific formula includes variations where R is H or a radical, and R' represents H or OH, ensuring that R and R' are not simultaneously H. His second patent focuses on new lupane derivatives, detailing their preparation and pharmaceutical compositions. These innovations highlight Gueguen's commitment to advancing medical science.

Career Highlights

Jean-Christophe Gueguen has worked with Rhone-Poulenc Rorer S.A., a company known for its dedication to pharmaceutical research and development. His role in this organization has allowed him to explore and develop new therapeutic options that can benefit patients worldwide.

Collaborations

Throughout his career, Gueguen has collaborated with esteemed colleagues such as Michel Evers and Serge Mignani. These partnerships have fostered an environment of innovation and creativity, leading to the successful development of his patented inventions.

Conclusion

Jean-Christophe Gueguen's contributions to the field of pharmaceuticals through his patents and collaborations demonstrate his dedication to improving healthcare. His work continues to inspire future innovations in medical treatments.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…